FDA Alters Carcinogenicity Testing of Compounds Used in Food Animals

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 2
Volume 7
Issue 2

ROCKVILLE, Md-The FDA has amended its regulations for testing the carcinogenicity of compounds used in food-producing animals to eliminate the specific requirement for “oral, chronic, dose-response studies.” The new wording states that bioassays “must be designed to assess carcinogenicity and to determine the quantitative aspects of any carcinogenic response.”

ROCKVILLE, Md—The FDA has amended its regulations for testing the carcinogenicity of compounds used in food-producing animals to eliminate the specific requirement for “oral, chronic, dose-response studies.” The new wording states that bioassays “must be designed to assess carcinogenicity and to determine the quantitative aspects of any carcinogenic response.”

When the existing regulation was issued, chronic studies were the standard. However, advances in carcinogenicity modeling have changed scientists’ views. For example, many researchers now agree that a chronic study “may not measure the appropriate time point necessary to assess carcinogenicity for some compounds,” the FDA said.

Recent Videos
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Related Content